Abstract
Since first identified, the epidemic scale of the recently emerged novel coronavirus (2019-nCoV) in Wuhan, China, has increased rapidly, with cases arising across China and other countries and regions. using a transmission model, we estimate a basic reproductive number of 3.11 (95%CI, 2.39–4.13); 58–76% of transmissions must be prevented to stop increasing; Wuhan case ascertainment of 5.0% (3.6–7.4); 21022 (11090–33490) total infections in Wuhan 1 to 22 January.
Changes to previous version
case data updated to include 22 Jan 2020; we did not use cases reported after this period as cases were reported at the province level hereafter, and large-scale control interventions were initiated on 23 Jan 2020;
improved likelihood function, better accounting for first 41 confirmed cases, and now using all infections (rather than just cases detected) in Wuhan for prediction of infection in international travellers;
improved characterization of uncertainty in parameters, and calculation of epidemic trajectory confidence intervals using a more statistically rigorous method;
extended range of latent period in sensitivity analysis to reflect reports of up to 6 day incubation period in household clusters;
removed travel restriction analysis, as different modelling approaches (e.g. stochastic transmission, rather than deterministic transmission) are more appropriate to such analyses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JMR and CPJ acknowledge support from the Medical Research Council (MR/5004793/1). JMR acknowledges support from the Engineering and Physical Sciences Research Council (EP/N014499/1). JREB acknowledges support from Faculty of Health and Medicine, Lancaster University in the form of a PhD Scholarship. CPJ acknowledges support from Wellcome.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The collated case and population data used for modelling is provided at a linked repository. Domestic and international airline passenger data are available via subscription from OAG (www.oag.com).
